FDA
-
-
-
-
-
-
-
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
-
-
-
-
-
-
-
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Avalo Therapuetics (AVTX) Appoints Garry Neil as CEO, Announces Additional Management Changes
-
-
-
-
-
-
-
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

